Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

PHASE3TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions
Relapsed Multiple MyelomaRelapsed-Refractory Multiple Myeloma
Interventions
DRUG

Melflufen

Powder for solution for i.v. infusion

DRUG

Dexamethasone

Oral tablets

DRUG

Daratumumab

Solution for s.c. injection

Trial Locations (26)

62500

University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno

Unknown

"University Multiprofile Hospital for Active Treatment Sveti Georgi, Plovdiv, Clinical Hematology Clinic", Plovdiv

Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia

University Hospital Hradec Kralove, 4th Internal Clinic of Hematology, Kralovice

University Hospital Ostrava, Clinic of Hematooncology, Ostrava-Poruba

General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology, Prague

JSC K. Eristavi National Center of Experimental and Clinical Surgery, Tbilisi

Malkhaz Katsiashvili Multiprofile EMC LTD, Tbilisi

St. Marien-Hospital Siegen gem. GmbH, Clinic for Hematology, Medical Oncology and Palliative Medicine, Siegen

Alexandra General Hospital, Therapeutic Clinic, Athens

"General Hospital of Athens Evangelismos, Department of Hematology and Lymphoma", Athens

Oslo University Hospital, Ulleval University Hospital, Oslo Myeloma Center, Oslo

Independent Public Healthcare Facility Municipal Hospitals, Teaching Department of Hematology And Prevention of Neoplastic Diseases, Chorzów

University Clinical Center, Teaching Department of Hematology and Transplantology, Gdansk

Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow

Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz, Lodz

St. John of Dukla Oncology Center of Lublin Region, Department of Hematology and Bone Marrow Transplantation, Lublin

Leningrad Regional Clinical Hospital, Saint Petersburg

V.D. Seredavin Samara Regional Clinical Hospital, Samara

Clinical Center of Serbia, Belgrade

Hospital Clinic of Barcelona, Department of Hematology, Barcelona

Cherkasy Regional Oncology Dispensary, Regional Treatment and Diagnostic Hematology Center, Cherkasy

Chernihiv Medical Center of Modern Oncology, Hematology Department, Chernihiv

City Clinical Hospital No. 4 City Hematology Center, Dnipro

Kyiv City Clinical Hospital No. 9, Hematology Department No. 1, Kyiv

National Institute of Cancer, Research Department of Hemoblastosis Chemotherapy and Adjuvant Treatment Methods, Department of Oncohematology with Adjuvant Treatment Methods Group, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oncopeptides AB

INDUSTRY